Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor
about
Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturationChemoselectivity in chemical biology: acyl transfer reactions with sulfur and seleniumThe human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycleImproved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulationsIn silico prediction of mutant HIV-1 proteases cleaving a target sequenceStructural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV proteaseCrystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: Comparisons with molecular modelingDiscovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding GroupCatalytic Water Co-Existing with a Product Peptide in the Active Site of HIV-1 Protease Revealed by X-Ray Structure AnalysisMolecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartatesThermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.A mean field model of ligand-protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor-specific bindingMutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein.The early years of retroviral protease crystal structures.Peptide interactions with G-protein coupled receptors.Crystal structure of HIV-1 protease in situ product complex and observation of a low-barrier hydrogen bond between catalytic aspartatesHuman immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA.Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutantsA preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor designCrystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis.Analysis of the structure of chemically synthesized HIV-1 protease complexed with a hexapeptide inhibitor. Part I: Crystallographic refinement of 2 A data.Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy.Dynamic and Electrostatic Effects on the Reaction Catalyzed by HIV-1 Protease.Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations.Movable lobes and flexible loops in proteins. Structural deformations that control biochemical activity.Fullerene-based inhibitors of HIV-1 protease.Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease.Structural engineering of the HIV-1 protease molecule with a beta-turn mimic of fixed geometry.Solid phase synthesis of the proteinase of bovine leukemia virus. Comparison of its specificity to that of HIV-2 proteinase.Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants.Interactions of a novel inhibitor from an extremophilic Bacillus sp. with HIV-1 protease: implications for the mechanism of inactivation.Empirical free energy as a target function in docking and design: application to HIV-1 protease inhibitors.
P2860
Q24555227-5F8FE95E-F0C8-431B-B83F-66F441C21089Q24625752-BBB9C6CB-8CCB-4F29-ACC9-E095CD659C80Q24685965-30A93D4F-204F-4134-9434-DB6A9463552FQ24794072-8295BB19-9637-495B-9757-743EA988A341Q27335448-BD66D98C-70DB-4423-8B7F-C8A607A47095Q27621075-1D53EBDF-1241-4ACB-83A0-2C156CA12DB5Q27642043-FC3E77DB-D562-4CDF-946C-B30D86751F35Q27644661-3A04FBEC-B461-4A92-9FF8-3D9172E4AC9AQ27658259-5A9AC46C-E35F-48A9-A64A-C95F320BD1ECQ28378646-58FCEE9C-38D5-4586-8369-0157F09433CEQ30480872-A9ACB092-25D4-4896-8FD6-DFA7D195ED98Q33597809-E3E406DE-95A5-4479-B1EE-D96958232EE1Q33638655-ECCF18FE-5720-4DE7-AE0B-9247DDDC3B76Q34121888-C184DA85-6723-49DD-B87E-617FE92536A7Q34483031-7DCAD89B-DB01-458E-A8E1-BD27B2E65B7CQ35214617-2445C51C-2AAF-4505-A1E7-F65A0773E9F2Q35823493-5749C2BB-0E0A-4AEE-821E-D29E68696597Q36034959-F452C0AD-8BB2-48C3-9676-6FEE41FDEEB2Q36279404-E5CDF507-CE7D-4E77-B662-FBDA2EB32611Q36529238-3521275C-0163-45B5-A01D-BFEC10052066Q36650046-0B6C5D48-B257-4FA5-A52A-090BF40AF4AAQ36718166-CAF06A4B-DC1C-4BD2-9B2F-2D5B806BCF74Q36849662-41345989-8D02-41A7-8BC1-447287BF1B72Q37334816-0BFADDDB-8D28-4C88-B326-C01E9B973FE4Q38785026-E91987D0-CAF4-456B-AABF-7EB73151C584Q40317435-28E0DA98-709A-454D-A447-E4DE4CCA4B08Q40822961-BEB520F7-29D9-4AE9-8409-A9BFB04A285FQ40976731-198F9AF0-4B01-4AA1-A7C3-C3F188B2CF69Q41816295-9E8424CE-DFE6-4206-95FF-BE65AE3D9DE5Q41840251-189EBDE6-1DBE-4472-A3FB-3554FDE79740Q42037444-30ADA7E5-20F1-4B31-AB01-68ADC136A7A9Q42845853-4099A7DC-2CA8-4B38-B469-6F0D8C80233DQ43508565-7C001E64-FD0B-47AC-B8C2-2381AAA3BF02Q52306807-7E291F1F-8F1B-4AB4-88E0-8C7EBC4172AD
P2860
Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor
description
1991 nî lūn-bûn
@nan
1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@ast
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@en
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@nl
type
label
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@ast
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@en
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@nl
prefLabel
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@ast
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@en
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@nl
P2093
P356
P1433
P1476
Structure at 2.5-A resolution ...... ydroxyethylene-based inhibitor
@en
P2093
A G Tomasselli
A Wlodawer
D G Staples
J Schneider
M Jaskólski
R L Heinrikson
T K Sawyer
P304
P356
10.1021/BI00220A023
P407
P577
1991-02-12T00:00:00Z